100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44DA043325
Award Date
3/1/17
Completion Date
12/21/20
Dollars Obligated
$1.5M
Overview
Activity
7
Transactions
7
Subawards
Similar Awards
Federal Agency
National Institute on Drug Abuse
Awardee
Brevitest Technologies, Inc. (G4L8ANC6ADL9)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Houston, TX 77027, USA
Update #1
Update #2
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE
Posted 3/4/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE - PROJECT SUMMARY BREVITEST TECHNOLOGIES, LLC, PROPOSES TO DEVELOP A LOW-COST, POINT-OF-CARE (POC) URINE DRUG TESTING (UDT) DEVICE TO DETECT OPIOIDS. THE GOAL IS FOR THE ASSAY PLATFORM TO DELIVER QUANTITATIVE PERFORMANCE SIMILAR TO A STANDARD LABORATORY ELISA. PHASE I RESEARCH AND DEVELOPMENT SHOWED THE REPEATABILITY AND ACCURACY OF BREVITEST'S PROPRIETARY ASSAY TECHNOLOGY. CURRENT DRUG-SCREENING IMMUNOASSAYS USE BENCHTOP ANALYZERS THAT REQUIRE EXPERIENCED PERSONNEL, TIME, AND A LABORATORY SETUP. PHYSICIANS WITHOUT ACCESS TO IN-HOUSE TESTING HAVE TO SEND OUT PATIENT SAMPLES FOR SCREENING, RESULTING IN UNACCEPTABLE DELAYS IN THE TREATMENT OF PATIENTS WHO ARE POTENTIALLY SUFFERING FROM CHRONIC PAIN. THUS MOST PHYSICIANS DO NOT FOLLOW THE FEDERAL RECOMMENDATIONS TO USE URINE DRUG TESTING (UDT) BEFORE PRESCRIBING OPIOIDS TO IDENTIFY POTENTIAL OPIOID ABUSE, EITHER FROM OVERDOSING (ABOVE EXPECTED LEVELS OF OPIOIDS IN URINE) OR INTENT TO RESELL (LOW OR ABSENT OPIOIDS DESPITE PATIENT CLAIMS TO THE CONTRARY). BREVITEST TECHNOLOGIES HAS DEVELOPED A LOW-COST, LAYMAN OPERABLE, POC ANALYZER TO PERFORM A QUANTITATIVE ELISA TEST WITHIN A 10-MINUTE RUN TIME. THE SAMPLE IS LOADED INTO A CARTRIDGE THAT IS PLACED IN THE ANALYZER AND AN AUTOMATED MECHANISM CONTROLS THE MOVEMENT OF ANTIBODY-CONJUGATED MAGNETIC MICROPARTICLES THROUGH SUCCESSIVE FLUID WELLS WITH ENHANCED MIXING PATTERNS. THIS INNOVATIVE APPROACH ENABLES THE IMPLEMENTATION OF A RAPID, PORTABLE, FULLY AUTOMATED ELISA TEST WITH ACCURACY COMPARABLE TO A STANDARD LABORATORY ELISA. THE SPECIFIC AIMS FOR THIS PHASE II PROJECT ARE: (1) FINALIZE DEVELOPMENT AND IMPLEMENTATION OF REPEATABILITY AND CALIBRATION PROTOCOLS ACCORDING TO INDUSTRY STANDARDS FOR THE DIAGNOSTIC DEVICE AND DISPOSABLE TEST CARTRIDGES; (2) BUILD AND CHARACTERIZE FULLY INTEGRATED PROTOTYPES TO OBTAIN A FINALIZED DEVICE DESIGN, PACKAGING, PROCESS, AND TOOLING; (3) PERFORM TESTING OF FINALIZED BREVITEST DEVICE AND PERFORMANCE VALIDATION USING PATIENT URINE SAMPLES. THE EXPECTED OUTCOME OF THIS PROJECT WILL BE A DEVICE DESIGNED FOR MANUFACTURING (DFM), BUILT AND CHARACTERIZED BY A CONTRACT MANUFACTURER, VALIDATED IN A PILOT STUDY AND USER SIMULATION, READY TO ENTER DESIGN CONTROLS, AND WITH A REGULATORY AND COMMERCIALIZATION PATH IN PLACE. BREVITEST OFFERS A UNIQUE PLATFORM TO CREATE AN ELISA TEST FOR PERFORMING RAPID QUANTIFICATIONS OF URINE DRUG LEVELS IN A PHYSICIAN'S OFFICE, PROVIDING AN INVALUABLE TOOL TO RENDER MORE EFFECTIVE PAIN MANAGEMENT DOSING TO PATIENTS, THUS PAVING THE WAY TOWARDS LOWER TOXICITY AND A BETTER QUALITY OF LIFE.
$0
5/22/21
Not listed
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE - PROJECT SUMMARY BREVITEST TECHNOLOGIES, LLC, PROPOSES TO DEVELOP A LOW-COST, POINT-OF-CARE (POC) URINE DRUG TESTING (UDT) DEVICE TO DETECT OPIOIDS. THE GOAL IS FOR THE ASSAY PLATFORM TO DELIVER QUANTITATIVE PERFORMANCE SIMILAR TO A STANDARD LABORATORY ELISA. PHASE I RESEARCH AND DEVELOPMENT SHOWED THE REPEATABILITY AND ACCURACY OF BREVITEST'S PROPRIETARY ASSAY TECHNOLOGY. CURRENT DRUG-SCREENING IMMUNOASSAYS USE BENCHTOP ANALYZERS THAT REQUIRE EXPERIENCED PERSONNEL, TIME, AND A LABORATORY SETUP. PHYSICIANS WITHOUT ACCESS TO IN-HOUSE TESTING HAVE TO SEND OUT PATIENT SAMPLES FOR SCREENING, RESULTING IN UNACCEPTABLE DELAYS IN THE TREATMENT OF PATIENTS WHO ARE POTENTIALLY SUFFERING FROM CHRONIC PAIN. THUS MOST PHYSICIANS DO NOT FOLLOW THE FEDERAL RECOMMENDATIONS TO USE URINE DRUG TESTING (UDT) BEFORE PRESCRIBING OPIOIDS TO IDENTIFY POTENTIAL OPIOID ABUSE, EITHER FROM OVERDOSING (ABOVE EXPECTED LEVELS OF OPIOIDS IN URINE) OR INTENT TO RESELL (LOW OR ABSENT OPIOIDS DESPITE PATIENT CLAIMS TO THE CONTRARY). BREVITEST TECHNOLOGIES HAS DEVELOPED A LOW-COST, LAYMAN OPERABLE, POC ANALYZER TO PERFORM A QUANTITATIVE ELISA TEST WITHIN A 10-MINUTE RUN TIME. THE SAMPLE IS LOADED INTO A CARTRIDGE THAT IS PLACED IN THE ANALYZER AND AN AUTOMATED MECHANISM CONTROLS THE MOVEMENT OF ANTIBODY-CONJUGATED MAGNETIC MICROPARTICLES THROUGH SUCCESSIVE FLUID WELLS WITH ENHANCED MIXING PATTERNS. THIS INNOVATIVE APPROACH ENABLES THE IMPLEMENTATION OF A RAPID, PORTABLE, FULLY AUTOMATED ELISA TEST WITH ACCURACY COMPARABLE TO A STANDARD LABORATORY ELISA. THE SPECIFIC AIMS FOR THIS PHASE II PROJECT ARE: (1) FINALIZE DEVELOPMENT AND IMPLEMENTATION OF REPEATABILITY AND CALIBRATION PROTOCOLS ACCORDING TO INDUSTRY STANDARDS FOR THE DIAGNOSTIC DEVICE AND DISPOSABLE TEST CARTRIDGES; (2) BUILD AND CHARACTERIZE FULLY INTEGRATED PROTOTYPES TO OBTAIN A FINALIZED DEVICE DESIGN, PACKAGING, PROCESS, AND TOOLING; (3) PERFORM TESTING OF FINALIZED BREVITEST DEVICE AND PERFORMANCE VALIDATION USING PATIENT URINE SAMPLES. THE EXPECTED OUTCOME OF THIS PROJECT WILL BE A DEVICE DESIGNED FOR MANUFACTURING (DFM), BUILT AND CHARACTERIZED BY A CONTRACT MANUFACTURER, VALIDATED IN A PILOT STUDY AND USER SIMULATION, READY TO ENTER DESIGN CONTROLS, AND WITH A REGULATORY AND COMMERCIALIZATION PATH IN PLACE. BREVITEST OFFERS A UNIQUE PLATFORM TO CREATE AN ELISA TEST FOR PERFORMING RAPID QUANTIFICATIONS OF URINE DRUG LEVELS IN A PHYSICIAN'S OFFICE, PROVIDING AN INVALUABLE TOOL TO RENDER MORE EFFECTIVE PAIN MANAGEMENT DOSING TO PATIENTS, THUS PAVING THE WAY TOWARDS LOWER TOXICITY AND A BETTER QUALITY OF LIFE.
$0
5/22/21
Not listed
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE - PROJECT SUMMARY BREVITEST TECHNOLOGIES, LLC, PROPOSES TO DEVELOP A LOW-COST, POINT-OF-CARE (POC) URINE DRUG TESTING (UDT) DEVICE TO DETECT OPIOIDS. THE GOAL IS FOR THE ASSAY PLATFORM TO DELIVER QUANTITATIVE PERFORMANCE SIMILAR TO A STANDARD LABORATORY ELISA. PHASE I RESEARCH AND DEVELOPMENT SHOWED THE REPEATABILITY AND ACCURACY OF BREVITEST'S PROPRIETARY ASSAY TECHNOLOGY. CURRENT DRUG-SCREENING IMMUNOASSAYS USE BENCHTOP ANALYZERS THAT REQUIRE EXPERIENCED PERSONNEL, TIME, AND A LABORATORY SETUP. PHYSICIANS WITHOUT ACCESS TO IN-HOUSE TESTING HAVE TO SEND OUT PATIENT SAMPLES FOR SCREENING, RESULTING IN UNACCEPTABLE DELAYS IN THE TREATMENT OF PATIENTS WHO ARE POTENTIALLY SUFFERING FROM CHRONIC PAIN. THUS MOST PHYSICIANS DO NOT FOLLOW THE FEDERAL RECOMMENDATIONS TO USE URINE DRUG TESTING (UDT) BEFORE PRESCRIBING OPIOIDS TO IDENTIFY POTENTIAL OPIOID ABUSE, EITHER FROM OVERDOSING (ABOVE EXPECTED LEVELS OF OPIOIDS IN URINE) OR INTENT TO RESELL (LOW OR ABSENT OPIOIDS DESPITE PATIENT CLAIMS TO THE CONTRARY). BREVITEST TECHNOLOGIES HAS DEVELOPED A LOW-COST, LAYMAN OPERABLE, POC ANALYZER TO PERFORM A QUANTITATIVE ELISA TEST WITHIN A 10-MINUTE RUN TIME. THE SAMPLE IS LOADED INTO A CARTRIDGE THAT IS PLACED IN THE ANALYZER AND AN AUTOMATED MECHANISM CONTROLS THE MOVEMENT OF ANTIBODY-CONJUGATED MAGNETIC MICROPARTICLES THROUGH SUCCESSIVE FLUID WELLS WITH ENHANCED MIXING PATTERNS. THIS INNOVATIVE APPROACH ENABLES THE IMPLEMENTATION OF A RAPID, PORTABLE, FULLY AUTOMATED ELISA TEST WITH ACCURACY COMPARABLE TO A STANDARD LABORATORY ELISA. THE SPECIFIC AIMS FOR THIS PHASE II PROJECT ARE: (1) FINALIZE DEVELOPMENT AND IMPLEMENTATION OF REPEATABILITY AND CALIBRATION PROTOCOLS ACCORDING TO INDUSTRY STANDARDS FOR THE DIAGNOSTIC DEVICE AND DISPOSABLE TEST CARTRIDGES; (2) BUILD AND CHARACTERIZE FULLY INTEGRATED PROTOTYPES TO OBTAIN A FINALIZED DEVICE DESIGN, PACKAGING, PROCESS, AND TOOLING; (3) PERFORM TESTING OF FINALIZED BREVITEST DEVICE AND PERFORMANCE VALIDATION USING PATIENT URINE SAMPLES. THE EXPECTED OUTCOME OF THIS PROJECT WILL BE A DEVICE DESIGNED FOR MANUFACTURING (DFM), BUILT AND CHARACTERIZED BY A CONTRACT MANUFACTURER, VALIDATED IN A PILOT STUDY AND USER SIMULATION, READY TO ENTER DESIGN CONTROLS, AND WITH A REGULATORY AND COMMERCIALIZATION PATH IN PLACE. BREVITEST OFFERS A UNIQUE PLATFORM TO CREATE AN ELISA TEST FOR PERFORMING RAPID QUANTIFICATIONS OF URINE DRUG LEVELS IN A PHYSICIAN'S OFFICE, PROVIDING AN INVALUABLE TOOL TO RENDER MORE EFFECTIVE PAIN MANAGEMENT DOSING TO PATIENTS, THUS PAVING THE WAY TOWARDS LOWER TOXICITY AND A BETTER QUALITY OF LIFE.
$0
1/8/21
Not listed
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE - PROJECT SUMMARY BREVITEST TECHNOLOGIES, LLC, PROPOSES TO DEVELOP A LOW-COST, POINT-OF-CARE (POC) URINE DRUG TESTING (UDT) DEVICE TO DETECT OPIOIDS. THE GOAL IS FOR THE ASSAY PLATFORM TO DELIVER QUANTITATIVE PERFORMANCE SIMILAR TO A STANDARD LABORATORY ELISA. PHASE I RESEARCH AND DEVELOPMENT SHOWED THE REPEATABILITY AND ACCURACY OF BREVITEST'S PROPRIETARY ASSAY TECHNOLOGY. CURRENT DRUG-SCREENING IMMUNOASSAYS USE BENCHTOP ANALYZERS THAT REQUIRE EXPERIENCED PERSONNEL, TIME, AND A LABORATORY SETUP. PHYSICIANS WITHOUT ACCESS TO IN-HOUSE TESTING HAVE TO SEND OUT PATIENT SAMPLES FOR SCREENING, RESULTING IN UNACCEPTABLE DELAYS IN THE TREATMENT OF PATIENTS WHO ARE POTENTIALLY SUFFERING FROM CHRONIC PAIN. THUS MOST PHYSICIANS DO NOT FOLLOW THE FEDERAL RECOMMENDATIONS TO USE URINE DRUG TESTING (UDT) BEFORE PRESCRIBING OPIOIDS TO IDENTIFY POTENTIAL OPIOID ABUSE, EITHER FROM OVERDOSING (ABOVE EXPECTED LEVELS OF OPIOIDS IN URINE) OR INTENT TO RESELL (LOW OR ABSENT OPIOIDS DESPITE PATIENT CLAIMS TO THE CONTRARY). BREVITEST TECHNOLOGIES HAS DEVELOPED A LOW-COST, LAYMAN OPERABLE, POC ANALYZER TO PERFORM A QUANTITATIVE ELISA TEST WITHIN A 10-MINUTE RUN TIME. THE SAMPLE IS LOADED INTO A CARTRIDGE THAT IS PLACED IN THE ANALYZER AND AN AUTOMATED MECHANISM CONTROLS THE MOVEMENT OF ANTIBODY-CONJUGATED MAGNETIC MICROPARTICLES THROUGH SUCCESSIVE FLUID WELLS WITH ENHANCED MIXING PATTERNS. THIS INNOVATIVE APPROACH ENABLES THE IMPLEMENTATION OF A RAPID, PORTABLE, FULLY AUTOMATED ELISA TEST WITH ACCURACY COMPARABLE TO A STANDARD LABORATORY ELISA. THE SPECIFIC AIMS FOR THIS PHASE II PROJECT ARE: (1) FINALIZE DEVELOPMENT AND IMPLEMENTATION OF REPEATABILITY AND CALIBRATION PROTOCOLS ACCORDING TO INDUSTRY STANDARDS FOR THE DIAGNOSTIC DEVICE AND DISPOSABLE TEST CARTRIDGES; (2) BUILD AND CHARACTERIZE FULLY INTEGRATED PROTOTYPES TO OBTAIN A FINALIZED DEVICE DESIGN, PACKAGING, PROCESS, AND TOOLING; (3) PERFORM TESTING OF FINALIZED BREVITEST DEVICE AND PERFORMANCE VALIDATION USING PATIENT URINE SAMPLES. THE EXPECTED OUTCOME OF THIS PROJECT WILL BE A DEVICE DESIGNED FOR MANUFACTURING (DFM), BUILT AND CHARACTERIZED BY A CONTRACT MANUFACTURER, VALIDATED IN A PILOT STUDY AND USER SIMULATION, READY TO ENTER DESIGN CONTROLS, AND WITH A REGULATORY AND COMMERCIALIZATION PATH IN PLACE. BREVITEST OFFERS A UNIQUE PLATFORM TO CREATE AN ELISA TEST FOR PERFORMING RAPID QUANTIFICATIONS OF URINE DRUG LEVELS IN A PHYSICIAN'S OFFICE, PROVIDING AN INVALUABLE TOOL TO RENDER MORE EFFECTIVE PAIN MANAGEMENT DOSING TO PATIENTS, THUS PAVING THE WAY TOWARDS LOWER TOXICITY AND A BETTER QUALITY OF LIFE.
$0
1/8/21
Not listed
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE
$511.3k
3/3/20